Virtual Science AI launches first AI-driven competitor activity tracking platform to support pharma asset launch success. Virtual Science AI Logo (PRNewsfoto/Virtual Science AI Ltd)

Medical Competitor AI uses AI to provide pharma companies with real-time competitor activity insights and scientific narrative analysis, supporting successful pharma product launches.

Virtual Science AI announces the launch of Medical Competitor AI, an AI solution that analyses competitor medical activity and scientific narratives. The solution, a first in the life sciences industry, is already being used by top pharma companies to drive launch success.

According to Towards Healthcare, the UK AI in life science market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 249.9 million in 2026 to approximately USD 1195.88 million by 2035, representing a compound annual growth rate (CAGR) of 19% from 2026 to 2035. Growth is driven by the Gen AI solution, which allows researchers to map target identification and Gen AI's vast genomic data and biological pathways to uncover promising novel drug candidates at an unprecedented speed. This model is fundamentally changing how targets are identified, cutting the time and expense associated with bringing novel therapeutics to market.

About Virtual Science AI

Virtual Science AI is a medically trained artificial intelligence platform. The company provides AI-driven tools to aggregate external stakeholder interactions, track competitor activity, and generate real-time medical insights.
The AI generates qualitative and quantitative reports immediately following stakeholder engagements, capturing tone, sentiment, and evolving industry trends. These platform tracks market narratives, community responses, and competitor milestones to give launch teams real-time visibility into therapeutic areas.

CEO, Virtual Science AI, Tom Hughes stated, "The teams behind the most important launches in pharma have historically had to piece together competitive intelligence manually or simply go without. Medical competitor AI changes that. It gives launch teams real-time visibility into competitor activity, scientific narratives, and community response, so they can make smarter decisions about where to focus and how to shape their story, and ultimately get more patients on the right treatments."

A recent report by Towards Healthcare highlights that the UK AI in life science market is witnessing growth due to the use of machine learning for computational drug design, target identification, and genomics. AI-driven platforms are drastically reducing the time and cost required to bring therapeutics for complex diseases to market.